Tag: USA

Poster-Quality of Life and Outcomes

Assessing Presence of MS-Related Symptoms As a Proxy for Disease Severity in Multiple Sclerosis Using Administrative Claims Data

Background: Healthcare claims data lack clinically relevant variables such as disease severity. Objectives: Assess multiple sclerosis...

Read More

Poster-Quality of Life and Outcomes

Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis

Background: Historically, there has been limited research on care partners of patients with multiple sclerosis (MS). Employers, health care...

Read More

Poster-Neuroimmunology and disease models

Comparing Infection-Related Outcomes By Sex in Patients with Multiple Sclerosis and Matched Controls Using Administrative Claims Data

Background: Few population-level sex-based risk estimates of specific infections exist for US patients with multiple sclerosis (MS)....

Read More

Poster-Imaging

Relationship of Functional Outcomes and Routinely Performed MRI Studies in Persons with Multiple Sclerosis: An Insight into the Frontal Lobe Structural Alterations

Background: Functional outcomes in multiple sclerosis (MS) have been thoroughly investigated over the last few decades. The Frontal lobe...

Read More

Poster-Disease-modifying Therapy

Classic-MS: Long-Term Efficacy and Real-World Treatment Patterns for Patients with Relapsing Multiple Sclerosis Who Received Cladribine Tablets in Phase III Parent Trials

Background: CLASSIC-MS (NCT03961204) explores the long-term efficacy and durability of effect of cladribine tablets (CladT; cumulative dose...

Read More

Poster-Disease-modifying Therapy

Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections and COVID-19

Background: Several integrated analyses have reported on the safety of cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years...

Read More

Poster-Disease-modifying Therapy

Click-MS: Cladribine Tablets in Patients with Relapsing Multiple Sclerosis after Suboptimal Response to Prior Injectable Disease-Modifying Therapy (Interim Analysis 1)

Background: The efficacy and safety of cladribine tablets 3.5 mg/kg (cumulative dose over 2 years) have been shown in patients with...

Read More

Poster-Disease-modifying Therapy

Baseline Characteristics and Adherence Among Multiple Sclerosis Patients Initiating Siponimod in Real World

Background: Siponimod was approved in the United States (US) in March 2019 for patients with relapsing forms of Multiple Sclerosis (MS)....

Read More